Watch BLFS. Know when insiders buy.
One email the day a filing lands. Free.
BLFS
BIOLIFE SOLUTIONS INC
35.38
+0.13 +0.37%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
83
PASS · shorts 83
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1.7BP/E 30.2DIV YIELD —FCF YIELD —REV TTM —NET INCOME $58MNET CASH $24M52W 18.15 – 37.22SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | $1.7M | $45.1M | — | 0.91 | $6.3M | $1M | $5.3M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | $27K | $1.2M | — | 0.02 | −$491K | $167K | −$658K | May 7 |
| Q4 2025 · Dec 31derived | — | — | — | $1.3M | $11.1M | −11.1% | 0.23 | $4.9M | — | — | Feb 26 |
| Q3 2025 · Sep 30 | — | — | — | −$89K | $621K | — | 0.01 | $6.1M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$16.1M | −$15.8M | — | -0.33 | $7.4M | $1.7M | $5.6M | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$499K | −$448K | — | 0.00 | $1.7M | $175K | $1.6M | May 7 |
| Q4 2024 · Dec 31derived | — | — | — | $542K | $12.5M | — | 0.27 | $1.6M | — | — | Feb 26 |
| Q3 2024 · Sep 30 | — | — | — | −$418K | −$1.7M | — | -0.04 | $4.8M | — | — | Nov 6 |
| Q2 2024 · Jun 30 | — | — | — | −$1.3M | −$20.7M | — | -0.45 | $6.5M | — | — | Aug 7 |
| Q1 2024 · Mar 31 | — | — | — | −$3.3M | −$10.2M | — | -0.22 | −$4.5M | — | — | May 8 |
| Q4 2023 · Dec 31derived | — | — | — | $17.5M | −$15M | — | -0.33 | $2.3M | $981K | $1.3M | Feb 26 |
| Q3 2023 · Sep 30 | — | — | — | −$15.5M | −$29.1M | — | -0.67 | −$4.4M | $1.5M | −$5.9M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$16.6M | −$4.6M | — | -0.10 | $20.1M | $9.5M | $10.6M | — | — |
| FY2024 · to Dec 31 | — | — | −$4.5M | −$20.2M | — | -0.44 | $8.4M | $3.2M | $5.2M | — | — |
| FY2023 · to Dec 31 | — | — | −$17.2M | −$68M | — | -1.55 | −$12.5M | $6.4M | −$18.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$5.9M | −$139.8M | — | -3.25 | −$8.5M | $10.4M | −$18.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$35.2M | −$8.9M | — | -0.23 | −$4.6M | $8.4M | −$13M | — | — |
| FY2020 · to Dec 31 | — | — | −$6.2M | $2M | — | -0.06 | $6.6M | $2M | $4.7M | — | — |
Every number comes from BIOLIFE SOLUTIONS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.